INVESTOR ALERT: The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Leerink Partnrs Has Positive Outlook of REGN Q4 Earnings
Investment analysts at Leerink Partnrs increased their Q4 2024 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, January 28th. Leerink Partnrs analyst ...
Zacks.com on MSN22h
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
Eli Lilly CEO Hasn’t Bought Company Shares in Years. He Just Bought This Stock.
Eli Lilly CEO David Ricks, also an Adobe director, paid $1 million on Jan. 28 for 2,250 shares of the software company.
The Armenian Reporter1h
Alvotech (NASDAQ:ALVOW) Sees Significant Drop in Short Interest
Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 11,800 shares, a drop of 38.2% from the ...